Latest News
AE Industrial Partners (AEI), a private equity firm specialising in aerospace, defence & government services, space, power & utility services, and specialty industrial markets, has appointed Charles Short as Managing Director and Head of Capital Formation, effective immediately.
Gen II Fund Services (Gen II), an independent private capital fund administrator, has appointed Nikolaos Perros as chief operating officer and Ishita Shah as chief commercial officer.
Perros is an experienced business executive with significant expertise in developing and implementing corporate strategy across various business verticals within the alternative asset and financial services industry. Most recently, Perros served as head of private equity at Citco Fund Services, where he was responsible for establishing and leading Citco’s private capital global service offering. Perros was also part of the Management Team of Citco Fund Services. Perros holds a BS in Accounting from
Mid-market private equity firm LDC has expanded its team of Value Creation Partners with the appointment of Cécile George as VCP director, to further enhance the support it provides for its portfolio of medium-sized firms.
With 20 years’ industry experience, George specialises in commercial strategy. In her role at LDC she will focus on helping the management teams across LDC’s portfolio to accelerate growth by optimising their sales, marketing and pricing strategies.
Prior to joining LDC, George supported private equity-backed companies – including those in the manufacturing, retail, technology and media sectors – to implement new pricing methodologies, enhance
Tiger Infrastructure Partners has appointed Danielle J Hunt as Chief Corporate Counsel, effective 1 October, 2022. Hunt joins Tiger from Allianz Global Investors, where she was Director and Associate General Counsel and served as both Global Head of Alternative Transactions Legal and Head of US Institutional Legal.
At Allianz Global Investors, Hunt led legal teams responsible for supporting the firm’s Private Markets platform focused on private equity and infrastructure investments across the US, Europe, and Asia. Hunt had leadership roles in various aspects of the platform’s legal needs, including transaction structuring, regulatory compliance, fund formation and strategic acquisitions.
Prior
Software-focused buyout house Thoma Bravo has agreed to make a significant growth investment in financial services automation solutions provider SMA Technologies.
SMA Technologies’ current majority investor, ParkerGale Capital, will retain a minority position in the business.
The firm said the investment will enable SMA to significantly expand its offering of automation solutions for its clients while accelerating growth geographically and into tangential industries over time.
Founded by automation experts at NASA in 1980, SMA helps eliminate manual tasks, reduce human error and free up resources through its workload automation platform.
Todd Dauchy, CEO of SMA Technologies, said: “SMA has been
HIG Capital’s portfolio company Aspire Pharma has acquired UK generic and branded specialty pharmaceuticals Morningside Healthcare and Morningside Pharmaceuticals.
Established in 1991, Morningside focuses on developing and licensing niche generic pharmaceutical products. It has over 160 SKUs across more than 80 product families including g Endocrine, Psychiatry, CNS, Infectious and Gastro.
HIG will combine Morningside with Aspire to build on their combined track record of organic growth, product development, and support new initiatives.
Rohin Jain, managing director of HIG European middle market and head of healthcare in Europe, added: “A combined Aspire and Morningside bring greater scale, breadth and diversity
Alternative investments firms saw a significant increase in interest in 2022, according to Peregrine Communications’ second annual Alts 50 report assessing the integrated marketing communications (IMC) performance of the alternative investment management industry.
The report found that nearly three-in-four (74%) firms saw increasing brand awareness over time. This is in stark contrast to the prevailing trend among long-only asset managers, where brand awareness has been in decline since 2018, according to Peregrine’s annual Global 100 study of the largest asset managers in the world.
When looking at how well firms marketed themselves as a whole, Blackstone maintained top spot overall
MJ Hudson an end-to-end solutions provider to the asset management industry, has published its Private Equity Fund Terms Research – Economics, Alignment and Governance for 2022.
Now in its seventh edition, the research is conducted by MJ Hudson’s Law practice and provides both LPs and GPs with an enhanced understanding of the current strengths and weaknesses of the fundamental economic, alignment and governance terms impacting private equity fund commitments. It includes comparisons with previously published research and discusses the factors driving change. It relates to buyout, venture, and growth funds.
Included is an examination of the core economics terms that
Clearwater Analytics Holdings, a provider of SaaS-based investment accounting, reporting, and analytics solutions, is to acquires Paris, France-based JUMP Technology, vastly expanding its capabilities in investment management and operations with a complete front-to-back solution.
Clearwater expects the acquisition to close within the next two months.
JUMP Technology, whose clients include market leaders Rothschild & Co Asset Management, Groupama, Groupe VYV, APICIL Asset Management, and Moneta Asset Management, has developed a modular, technology platform that is dedicated to the investment management industry spanning investment managers, hedge funds, private banks, family offices, insurers, and institutional investors.
The JUMP solution covers
CXL Ophthalmics, a clinical-stage company developing a minimally-invasive treatment for keratoconus, has raised a $32 million Series A funding round led by AXA IM Alts through its Global Health Private Equity strategy plus a syndicate of individual investors, including leading cornea specialists.
The new investments will support the advancement of CXL Ophthalmics’ (CXLO) transformative cross-linking system, EpiSmart, through Phase 3 trials on the way to a New Drug Application with FDA.
EpiSmart is CXLO’s transformative cross-linking system targeting keratoconus, a common type of corneal ectasia. EpiSmart is designed to be highly effective and minimally invasive with reduced discomfort, plus a
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
